GlassScriptPhysician profile
Deborah A Moore
NPI 1316021926
$6,422.51
in general payments reported to CMS, 2019-2025
13 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $744 · 2022: $1,448 · 2023: $2,344 · 2024: $820 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.94 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,307.28 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,283.32 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,258.35 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $665.60 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $489.37 | 2023-2025 | Auvelity |
| Abbvie INC. | $341.56 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $289.94 | 2021-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $238.33 | 2022-2023 | Uzedy, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $204.00 | 2022-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $129.47 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $104.24 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $91.88 | 2022-2025 | Rexulti |
| Octapharma USA, INC. | $19.17 | 2024 | Balfaxar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.